Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2018-06-13 Regulatory Filings
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
LOXL2 Program Attracts Strong Partner Interest at BIO18 2 pages 125.1KB
Regulatory Filings Classification · 95% confidence The document is a media release dated 14 June 2018 from Pharmaxis Ltd discussing the progress and interest in their LOXL2 inhibitor program entering the final stage of phase 1 clinical trials. It highlights clinical trial results, safety profiles, and ongoing partnering discussions with pharmaceutical companies. There is no detailed financial data, regulatory form references, or comprehensive financial reporting. The content is a corporate announcement about drug development progress and business development activities rather than a financial report or regulatory filing. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is a press release or media announcement about clinical trial progress and partnering interest, which aligns best with a general Regulatory Filings (RNS) category as a fallback for miscellaneous announcements that do not fit other specific categories.
2018-06-13 English
Appendix 4C - quarterly 5 pages 210.9KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C' and is described as a 'Quarterly report for entities subject to Listing Rule 4.7B'. It contains detailed consolidated cash flow statements for the current quarter and year-to-date nine months, including operating, investing, and financing activities. It also includes notes on payments to directors, financing facilities, estimated cash outflows for the next quarter, and compliance statements. The presence of substantive financial data and analysis for a period shorter than a full fiscal year (quarterly) aligns with the definition of an Interim / Quarterly Report (IR). The document is not merely an announcement or certification but contains actual financial statements and explanatory notes. Therefore, the correct classification is IR with high confidence. Q3 2018
2018-04-29 English
Quarterly Shareholder Update - March 2018 9 pages 378.6KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Quarterly Shareholder Update – March 2018' and contains detailed financial metrics for the three and nine months ended 31 March 2018, including income statements, segment results, and cash flow statements. It discusses operational highlights, drug development progress, and market updates. The presence of substantive financial data and analysis for a quarter, along with business updates, indicates this is a comprehensive interim or quarterly report rather than a brief announcement or presentation. The length of the document (15,000 characters) and the detailed financial tables further support this classification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2018
2018-04-29 English
Change in substantial holding 3 pages 221.9KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 604 under the Corporations Act 2001, Section 671B, which is a notice of change of interests of a substantial holder. It details changes in voting power and shareholdings of significant shareholders in Pharmaxis Ltd. This type of filing is a notification of major shareholding changes, not a financial report or other corporate filing. Therefore, it fits the category of Major Shareholding Notification (MRQ). The document length and content confirm it is not an announcement or a report but a formal notification of shareholding changes.
2018-04-04 English
Appendix 3B - Exercise of Employee Options 11 pages 134.6KB
Capital/Financing Update Classification · 95% confidence The document is titled 'Appendix 3B' and is an announcement related to the issue of new securities, specifically the issuance of fully paid ordinary shares upon exercise of options under an employee option plan. It includes details such as the number of securities issued, class of securities, issue price, purpose of the issue, and dates. The document references ASX rules and is clearly a formal announcement to the Australian Securities Exchange regarding a capital raising event or share issuance. It does not contain financial statements, management discussion, or audit information. It is not a report but an announcement of a capital/financing update. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length is substantial and contains detailed information about the securities issued, supporting a high confidence in classification.
2018-03-07 English
Half Yearly Report and Accounts 23 pages 248.3KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'ASX Half year report – 31 December 2017' and references the half-year ended 31 December 2017, with comparative data for the previous half-year period. It includes detailed financial statements such as consolidated income statement, balance sheet, cash flows, notes to financial statements, directors' report, and auditor's review report. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement. The content includes comprehensive financial data and management discussion typical of an interim or quarterly report. The document explicitly states it is a half-year report and is lodged under ASX Listing Rule 4.2A, which corresponds to interim financial reporting requirements. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2018
2018-02-14 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.